{"id":34940,"date":"2025-08-11T11:20:05","date_gmt":"2025-08-11T09:20:05","guid":{"rendered":"https:\/\/ggba.swiss\/azurecell-therapies-and-myriad-optics-awarded-by-gebert-ruf-stiftungs-innobooster-programme\/"},"modified":"2025-08-11T11:22:27","modified_gmt":"2025-08-11T09:22:27","slug":"azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/","title":{"rendered":"AzureCell Therapies et Myriad Optics r\u00e9compens\u00e9es par le programme Innobooster de la Gebert R\u00fcf Stiftung"},"content":{"rendered":"\n

Spin-off de l\u2019Universit\u00e9 de Gen\u00e8ve, AzureCell Therapies<\/a> met au point une nouvelle g\u00e9n\u00e9ration de th\u00e9rapies cellulaires r\u00e9g\u00e9n\u00e9ratives pour la maladie de Parkinson et d\u2019autres troubles neurod\u00e9g\u00e9n\u00e9ratifs. L\u2019approche de l\u2019entreprise repose sur 18 ans de recherche et un portefeuille de cinq brevets, afin de produire \u00e0 grande \u00e9chelle des neurones producteurs de dopamine \u00e0 partir de cellules souches, tout en garantissant leur s\u00e9curit\u00e9 et leur durabilit\u00e9. En programmant ces neurones cultiv\u00e9s en laboratoire pour r\u00e9duire le risque tumoral et am\u00e9liorer leur survie apr\u00e8s transplantation dans le cerveau, AzureCell vise \u00e0 proposer un traitement curatif capable de restaurer les circuits neuronaux et d\u2019offrir des b\u00e9n\u00e9fices durables aux patients.<\/p>\n\n\n\n

La start-up a r\u00e9cemment s\u00e9curis\u00e9 plus de CHF 1 million de financement en amont de son incorporation pr\u00e9vue au troisi\u00e8me trimestre 2025, notamment gr\u00e2ce au soutien de Venture Kick<\/a>. La bourse Innobooster<\/a> permettra de renforcer sa plateforme de production, d\u2019acc\u00e9l\u00e9rer sa transition vers les normes de bonnes pratiques de fabrication (GMP) et de soutenir les pr\u00e9paratifs de d\u00e9veloppement clinique.<\/p>\n\n\n\n

Fond\u00e9e \u00e0 l\u2019EPFL, Myriad Optics<\/a> s\u2019attaque aux enjeux de s\u00e9curit\u00e9 alimentaire en r\u00e9duisant drastiquement le temps n\u00e9cessaire \u00e0 la d\u00e9tection des bact\u00e9ries pathog\u00e8nes dans l\u2019industrie alimentaire. Les m\u00e9thodes actuelles peuvent n\u00e9cessiter jusqu\u2019\u00e0 cinq jours pour fournir un r\u00e9sultat, retardant les interventions et augmentant les risques de contamination, de gaspillage et de rappels co\u00fbteux. La technologie de Myriad Optics combine la spectroscopie Raman et la microfluidique pour obtenir une d\u00e9tection fiable en quelques heures, r\u00e9duisant le d\u00e9lai de 75 \u00e0 95%. Ce syst\u00e8me portable et facile \u00e0 utiliser vise \u00e0 am\u00e9liorer les processus de contr\u00f4le qualit\u00e9 tout en restant abordable pour une adoption industrielle.<\/p>\n\n\n\n

Quatre autres projets universitaires ont \u00e9galement \u00e9t\u00e9 r\u00e9compens\u00e9s : ZuriEV (ETH Zurich) d\u00e9veloppe une biopsie liquide pour la d\u00e9tection pr\u00e9coce du cancer ; AITHON Robotics (ETH Zurich) propose une inspection d\u2019infrastructures plus rapide et moins co\u00fbteuse ; FireDrone (EMPA) con\u00e7oit un drone capable d\u2019op\u00e9rer dans des environnements jusqu\u2019\u00e0 200\u00b0C ; et Xelerit (ETH Zurich) d\u00e9veloppe un logiciel bas\u00e9 sur l\u2019IA pour optimiser les lignes de production.<\/p>\n","protected":false},"excerpt":{"rendered":"

Deux start-ups de la Health Valley en Suisse occidentale, AzureCell Therapies et Myriad Optics, ont chacune re\u00e7u une bourse de CHF 150\u2019000 dans le cadre du programme Innobooster de la Gebert R\u00fcf Stiftung, qui soutient des projets \u00e0 fort potentiel issus des universit\u00e9s suisses.<\/p>\n","protected":false},"author":6,"featured_media":34937,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1162,1148,1166,1188,1140,1142],"class_list":["post-34940","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-education-en-fr","tag-financing-fr-2","tag-food-beverages-fr-2","tag-healthcare-fr-2","tag-oncology-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"\nAzureCell et Myriad r\u00e9compens\u00e9es par la Gebert R\u00fcf Stiftung<\/title>\n<meta name=\"description\" content=\"AzureCell Therapies et Myriad Optics, ont chacune re\u00e7u CHF 150\u2019000 dans le cadre du programme Innobooster de la Gebert R\u00fcf Stiftung.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AzureCell et Myriad r\u00e9compens\u00e9es par la Gebert R\u00fcf Stiftung\" \/>\n<meta property=\"og:description\" content=\"AzureCell Therapies et Myriad Optics, ont chacune re\u00e7u CHF 150\u2019000 dans le cadre du programme Innobooster de la Gebert R\u00fcf Stiftung.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-11T09:20:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-11T09:22:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AzureCell Therapies et Myriad Optics r\u00e9compens\u00e9es par le programme Innobooster de la Gebert R\u00fcf Stiftung\",\"datePublished\":\"2025-08-11T09:20:05+00:00\",\"dateModified\":\"2025-08-11T09:22:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/\"},\"wordCount\":399,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Education\",\"Financing\",\"Food & Beverages\",\"Healthcare\",\"Oncology\",\"R&D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/\",\"name\":\"AzureCell et Myriad r\u00e9compens\u00e9es par la Gebert R\u00fcf Stiftung\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png\",\"datePublished\":\"2025-08-11T09:20:05+00:00\",\"dateModified\":\"2025-08-11T09:22:27+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"AzureCell Therapies et Myriad Optics, ont chacune re\u00e7u CHF 150\u2019000 dans le cadre du programme Innobooster de la Gebert R\u00fcf Stiftung.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"AzureCell Therapies d\u00e9veloppe des th\u00e9rapies cellulaires r\u00e9g\u00e9n\u00e9ratives pour les maladies neurod\u00e9g\u00e9n\u00e9ratives, tandis que Myriad Optics con\u00e7oit des syst\u00e8mes rapides de d\u00e9tection des agents pathog\u00e8nes pour la s\u00e9curit\u00e9 alimentaire.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AzureCell Therapies et Myriad Optics r\u00e9compens\u00e9es par le programme Innobooster de la Gebert R\u00fcf Stiftung\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AzureCell et Myriad r\u00e9compens\u00e9es par la Gebert R\u00fcf Stiftung","description":"AzureCell Therapies et Myriad Optics, ont chacune re\u00e7u CHF 150\u2019000 dans le cadre du programme Innobooster de la Gebert R\u00fcf Stiftung.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/","og_locale":"fr_FR","og_type":"article","og_title":"AzureCell et Myriad r\u00e9compens\u00e9es par la Gebert R\u00fcf Stiftung","og_description":"AzureCell Therapies et Myriad Optics, ont chacune re\u00e7u CHF 150\u2019000 dans le cadre du programme Innobooster de la Gebert R\u00fcf Stiftung.","og_url":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-08-11T09:20:05+00:00","article_modified_time":"2025-08-11T09:22:27+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AzureCell Therapies et Myriad Optics r\u00e9compens\u00e9es par le programme Innobooster de la Gebert R\u00fcf Stiftung","datePublished":"2025-08-11T09:20:05+00:00","dateModified":"2025-08-11T09:22:27+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/"},"wordCount":399,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png","keywords":["Biotech","Education","Financing","Food & Beverages","Healthcare","Oncology","R&D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/","url":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/","name":"AzureCell et Myriad r\u00e9compens\u00e9es par la Gebert R\u00fcf Stiftung","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png","datePublished":"2025-08-11T09:20:05+00:00","dateModified":"2025-08-11T09:22:27+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"AzureCell Therapies et Myriad Optics, ont chacune re\u00e7u CHF 150\u2019000 dans le cadre du programme Innobooster de la Gebert R\u00fcf Stiftung.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Azurecell-Myriad-1180x811-1.png","width":1180,"height":811,"caption":"AzureCell Therapies d\u00e9veloppe des th\u00e9rapies cellulaires r\u00e9g\u00e9n\u00e9ratives pour les maladies neurod\u00e9g\u00e9n\u00e9ratives, tandis que Myriad Optics con\u00e7oit des syst\u00e8mes rapides de d\u00e9tection des agents pathog\u00e8nes pour la s\u00e9curit\u00e9 alimentaire."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/azurecell-therapies-et-myriad-optics-recompensees-par-le-programme-innobooster-de-la-gebert-ruf-stiftung\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"AzureCell Therapies et Myriad Optics r\u00e9compens\u00e9es par le programme Innobooster de la Gebert R\u00fcf Stiftung"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=34940"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34940\/revisions"}],"predecessor-version":[{"id":34942,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34940\/revisions\/34942"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/34937"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=34940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=34940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=34940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}